UBS Maintains Sell on Medtronic, Raises Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Matthew Taylor maintains a Sell rating on Medtronic (NYSE:MDT) but raises the price target from $75 to $76.
May 24, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst Matthew Taylor maintains a Sell rating on Medtronic but raises the price target from $75 to $76.
The Sell rating suggests a negative outlook, but the slight increase in the price target indicates some positive factors. Overall, the impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100